Phase 2 N=29 Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
Corona Virus Infection · SARS-CoV 2 · SARS Pneumonia
Primary: Number of Participants Transferred to Intensive Care Unit (ICU) — 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=80 COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
COVID-19
Primary: Participants With Serious Adverse Events. — 12; 15 Participants
N/A N=69 Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19
Covid19
Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants
Phase 2 N=18 Dual MRI for Cardiopulmonary COVID-19 Long Haulers
Covid19
Primary: Red Blood Cell to Membrane (RBC:M) Ratio — 0.39; 0.51 ratio (RBC:M)
N/A N=417 The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19
COVID-19
Primary: Mechanical Ventilation — 21 Participants
N/A N=224 Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS
Prone Positioning · High Flow Nasal Cannula · Acute Respiratory Distress Syndrome
Primary: Treatment Failure (Intubation or Death) — 45; 45 Participants
Phase 2 N=25 Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
Covid19 · Pneumonia, Viral
Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…
Phase 2 N=5 Treat COVID-19 Patients With Regadenoson
COVID-19 · Lung Inflammation
Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free
Phase 2 N=149 Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
Coronavirus Disease 2019
Primary: Time to Recovery — 3.4; 3.7; 3.9 Days
Phase 2 N=30 Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.
Covid19 · SARS-CoV-2 PNEUMONIA · COVID-19
Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants
N/A N=119 Myocardial Injury and Quality of Life After COVID-19
COVID-19 · Myocardial Injury · Myocarditis Post Infection
Primary: Percentage of Patients (%) Recovered From COVID-19 With a Decrease in the Global Contractility of the Left and Right Ventricles. — 19; 39; 48 Participants
Phase 2 N=228 CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)
Corona Virus Infection
Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 19; 28…
N/A N=203 The Place of Imaging and Microbiology in the Diagnosis of Pneumonia in the Elderly
Pneumonia
Primary: Number of Patients With Modified Diagnosis Probability After Low Dose CT (LDCT) — 10; 3; 4; 34 Participants
Phase 2 N=143 Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia
COVID-19 Pneumonia, Impaired Respiratory Function
Primary: APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier) — 8.7; 8.6 Score on a scale — p=0.467
Phase 1 N=12 Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
COVID · Sars-CoV2 · COVID-19
Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants
Phase 2 N=36 Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
SARS-CoV-2 (COVID-19) Severe Pneumonia
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 8; 7; 7; 5 Participants
N/A N=384 Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19
Covid19
Primary: Hospitalists Who Adopt Lung Ultrasound — 4 Participants
Phase 2 N=47 Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)
COVID-19
Primary: Number of Participants Requiring Mechanical Ventilation or Dying — 3; 3 Participants
Phase 2 N=53 Nebulised Rt-PA for ARDS Due to COVID-19
COVID
Primary: Efficacy - PaO2/FiO2 Ratio — 227; 209; 155; 248 mmHg (rounded)
Phase 2 N=83 Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
COVID-19 Pneumonia · Acute Lung Injury · ARDS
Primary: Number of Subjects Alive and Free of Respiratory Failure — 26; 20 Participants — p=0.0440
Phase 2 N=200 Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
SARS (Severe Acute Respiratory Syndrome) · Coronavirus
Primary: Change of Arterial Oxygenation at 48 Hours From Enrollment — 200; 183 ratio
Phase 2 N=124 Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
Covid-19
Primary: Recover Ratio — 47; 48; 1; 0 Participants
Phase 2 N=97 A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia
COVID-19 Pneumonia
Primary: Area Under the Curve From Day 0-28 (AUC0-d28) of Tocilizumab) — 371; 849; 837; 1330 µg/mL*day
Phase 2 N=41 Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019)
COVID-19 (Coronavirus Disease 2019) · Hypoxia
Primary: Measuring the Change in Inflammation — 23.23; 34.82 mg/L — p=0.01
Phase 2 N=101 The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
COVID-19
Primary: Number of Participants With Worsening of COVID-19 Within 28 Days — 1; 1 Participants
N/A N=75 Urease Breath Test for Rapid Characterization of Pneumonia
Pneumonia, Bacterial
Primary: Adverse Events — 3; 0; 1; 0 Participants
Phase 2 N=64 Rhu-pGSN for Severe Covid-19 Pneumonia
Sars-CoV2
Primary: Efficacy: Proportion of Subjects Alive Not on Vasopressors, Mechanical Ventilator, or Dialysis — 27; 25 participants — p=>0.05
Phase 3 N=438 A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia
COVID-19 Pneumonia
Primary: Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 28 (Week 4) — 56.5; 49.3; 2.0; 5.6 Percentage of Participants — p=0.3600
Phase 3 N=30 Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
SARS-CoV 2 · ARDS
Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg
Phase 2 N=32 Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis
COVID-19
Primary: Number of Participants With Clinical Response in Maximum Temperature (Tmax) — 8; 16 Participants